News
MHRA licenses Ryeqo for symptoms of uterine fibroids
The Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Gedeon Richter UK’s Ryeqo (relugolix combination therapy) for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.